HPV vaccination South Africa: Cervical Cancer Prevention

By Crystal Lubbe

November 21, 2024

Since the launch of South Africa’s HPV vaccination program, the country has made notable progress in addressing cervical cancer. The HPV vaccination program, introduced in 2014, specifically targets 9-year-old girls in grade four across over 12,000 public schools. Despite challenges posed by the COVID-19 pandemic, the program has achieved impressive vaccination coverage rates. Furthermore, averaging between 70% to 80% prior to the pandemic’s disruption.

Program Implementation and Coverage

The national HPV vaccination program is integrated into the Integrated School Health Program. Therefore, utilising school nurses and a dedicated workforce of vaccinators. This effective delivery method is crucial for reaching the intended target population.

Vaccine Efficacy and Single-Dose Regimen

Global studies reveal that HPV vaccines can decrease cervical cancer rates by up to 90% in girls who receive the vaccination. The recent consideration of a single-dose regimen is promising, as it could streamline the vaccination process and lower the costs associated with the immunization campaign.

Impact on Cervical Cancer

Approximately 70% of cervical cancer cases worldwide are linked to HPV types 16 and 18. By preventing these infections through the HPV vaccination program, South Africa aims to significantly reduce not only the incidence of cervical cancer but also other anogenital cancers.

Challenges and Additional Strategies

Women living with HIV (WLHIV) face a heightened risk of developing cervical cancer. To combat this issue, additional strategies, including more frequent cervical screenings for WLHIV, are being explored to work towards the elimination of cervical cancer among this demographic.

Public Health and Policy Implications

The successful implementation of South Africa’s HPV vaccination program positions it as a model for other nations, aligning with the World Health Organization’s initiative to eradicate cervical cancer as a public health problem. Furthermore, the program’s infrastructure supports broader adolescent health efforts.

Funding and Advocacy

The ongoing success of the HPV vaccination program relies on dedicated funding and robust advocacy. Framing the vaccination as a vital cancer prevention tool, rather than merely a defense against a sexually transmitted infection, has bolstered public support for the initiative.

In summary, South Africa’s HPV vaccination program exemplifies significant progress in combating cervical cancer. With strong coverage rates, integration into school health services, the exploration of a single-dose regimen, and targeted strategies for at-risk groups, the nation is setting a positive example for others to follow.

Reference url

Recent Posts

Developer Engagement Misalignment: Challenges in Assessing Advanced Therapies

By João L. Carapinha

May 11, 2026

Advanced Therapy Medicinal Products (ATMPs) offer transformative options for rare and previously untreatable conditions, yet their high upfront costs, uncertain durability, and single-arm trial data create major reimbursement barriers. The 2026 pre-proof study by Greco et al. shows that developer...
MEA Adoption Challenges in Advanced Therapy Medicinal Products: Insights and Implications
MEA Adoption Challenges continue to limit the practical use of Managed Entry Agreements for Advanced Therapy Medicinal Products across Europe. The 2026 pre-proof paper by Greco et al. draws on interviews with HTA bodies and payers in England, the Netherlands, and Spain to show that hybrid agreeme...
Compliance Challenges Under the New Procurement Regulations South Africa for Health Sector Suppliers

By João L. Carapinha

May 8, 2026

South Africa’s Draft General Public Procurement Regulations, 2026 establish a comprehensive framework that prioritises transparency, accountability and value for money in all public contracts under procurement regulations South Africa. For pharmaceutical, biotech and medtech companies bidding on ...